bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that Nick Leschly, chief bluebird, will present at the 34th annual J.P. Morgan Healthcare Conference onTuesday, January 12, 2016 at 4:00 p.m. PST. The conference is being held January 11-14, 2016 at the Westin St. Francis in San Francisco.

To access the live webcast of bluebird bio’s presentation and subsequent breakout session, please visit the “Calendar of Events” page within the Investors and Media section of the bluebird bio website at Replays of the webcast will be available on the bluebird bio website for 90 days following the conference. (Original Source)

Shares of bluebird bio Inc closed yesterday at $63.47, down $0.75 or -1.17%. BLUE has a 1-year high of $197.35 and a 1-year low of $48.85. The stock’s 50-day moving average is $70.76 and its 200-day moving average is $112.14.

On the ratings front, bluebird bio Inc (NASDAQ: BLUE) has been the subject of a number of recent research reports. In a report released today, Piper Jaffray analyst Joshua Schimmer maintained a Buy rating on BLUE, with a price target of $125, which represents a potential upside of 96.9% from where the stock is currently trading. Separately, on December 7, Jefferies Co.’s Gena Wang maintained a Buy rating on the stock and has a price target of $96.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joshua Schimmer and Gena Wang have a total average return of -3.3% and -12.7% respectively. Schimmer has a success rate of 43.4% and is ranked #3353 out of 3648 analysts, while Wang has a success rate of 40.0% and is ranked #3210.

The street is mostly Bullish on BLUE stock. Out of 12 analysts who cover the stock, 8 suggest a Buy rating and 4 recommend to Hold the stock. The 12-month average price target assigned to the stock is $111.17, which implies an upside of 75.2% from current levels.

bluebird bio Inc is a clinical-stage biotechnology company. It is engaged in developing potentially transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy.